Literature DB >> 87614

Combination chemotherapy with cis-diammine-dichloro-platinum, vinblastine, and bleomycin in advanced testicular non-seminoma.

G Stoter, D T Sleijfer, C P Vendrik, H Schraffordt Koops, A Struyvenberg, A T Van Oosterom, T M Brouwers, H M Pinedo.   

Abstract

40 patients with disseminated testicular non-seminoma were treated with cis-diammine-dichloro-platinum, vinblastine, and bleomycin. Complete remission was achieved in 24 (60%) patients and partial remission in 11 (28%). 22 of the 24 complete responders, who have been followed-up for a median of 11 months, have been tumour-free for 5--30 months. There were 3 drug-related deaths. This regimen is the most effective remission-induction treatment available for disseminated testicular non-seminoma. Patients should be treated in centres experienced in the specialised management of this potentia-ly curable disease.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 87614     DOI: 10.1016/s0140-6736(79)91719-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  8 in total

1.  Chemotherapy for non-seminomatous germ-cell tumours.

Authors:  P M Wilkinson
Journal:  J R Soc Med       Date:  1985       Impact factor: 5.344

Review 2.  Commentary: combination chemotherapy of nonseminomatous testicular cancer.

Authors:  S K Carter; F M Torti
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

Review 3.  Cisplatin: a review of clinical applications and renal toxicity.

Authors:  D T Sleijfer; S Meijer; N H Mulder
Journal:  Pharm Weekbl Sci       Date:  1985-12-13

4.  Absence of relation between nutritional parameters and renal function in non-seminomatous testicular cancer patients.

Authors:  J A Gietema; E G de Vries; S Meijer; J J Offerman; P O Mulder; D T Sleijfer
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

5.  Nephrotoxicity of cis-diamminedichloride platinum (CDDP) during remission-induction and maintenance chemotherapy of testicular carcinoma.

Authors:  S Meijer; N H Mulder; D T Sleijfer; P E de Jong; W J Sluiter; H Schraffordt Koops; G K van der Hem
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

6.  Antipyrine metabolism in patients with disseminated testicular cancer and the influence of cytostatic treatment.

Authors:  M W Teunissen; P H Willemse; D T Sleijfer; W J Sluiter; D D Breimer
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

7.  The timing of introduction of pharmaceutical innovations in seven European countries.

Authors:  Ragnar Westerling; Marcus Westin; Martin McKee; Rasmus Hoffmann; Iris Plug; Grégoire Rey; Eric Jougla; Katrin Lang; Kersti Pärna; José L Alfonso; Johan P Mackenbach
Journal:  J Eval Clin Pract       Date:  2014-04-22       Impact factor: 2.431

8.  Chemotherapy of advanced malignant teratomas.

Authors:  E S Newlands; R H Begent; S B Kaye; G J Rustin; K D Bagshawe
Journal:  Br J Cancer       Date:  1980-09       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.